COMMUNIQUÉS West-GlobeNewswire

The Ensign Group Expands in California
02/04/2025
SAN JUAN CAPISTRANO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
Helsinn Group submits a new formulation of AKYNZEO® to the European Medicines Agency (EMA)
02/04/2025
Lugano, Switzerland – April 2, 2025 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of nearly fifty years of commercial execution and a strong focus in supportive care, oncology and [...]
AVEROA Receives Positive Opinion from the European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD)
02/04/2025
CHMP recommends approval for XOANACYL, an oral therapy for use in the following therapeutic areas: Iron deficiency, chronic renal failure and hyperphosphatemia Final European Commission decision expected by June 2025; [...]
Boehringer Ingelheim reaches more patients in 2024 and prepares new medicine launches
02/04/2025
Number of patients reached in 2024 jumps 8% to 66 million R&D investments rise to EUR 6.2 billion, 23.2% of group net sales Company prepares new product launches starting in 2025 Boehringer Ingelheim today announced [...]
ENA Respiratory Announces Publication Supporting the Potential of its Novel Intranasal Therapy INNA-051 to Reduce the Impact of Viral Respiratory Infections in Older Adults
02/04/2025
Clinical studies demonstrated that INNA-051’s natural defence boosting mechanism is effective in older adults Administration of INNA-051 to older adults (65 years old) in a Phase 1 study was well-tolerated and increased [...]
CMR Surgical secures more than $200M to accelerate growth
02/04/2025
CMR Surgical has closed a financing round of more than $200 million, backed by existing investors and new investor Trinity Capital The latest funding will fuel the global commercialisation of its Versius Surgical [...]
Press Release Biocartis NV: Biocartis Announces Launch of the Brand-New Idylla™ POLE-POLD1 Mutation Assay
02/04/2025
PRESS RELEASE 02/04/2025, 07:00 CEST Biocartis Announces Launch of the Brand-New Idylla™ POLE-POLD1 Mutation Assay Mechelen, Belgium, 02 April 2025 – Biocartis NV (“Biocartis”), an innovative molecular diagnostics [...]
Zelluna ASA [ZLNA]: Annual Report 2024
02/04/2025
Oslo, Norway, 02 April, 2025 - Zelluna ASA, a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces that the Board of Directors of [...]
IBA signs contract for a Proteus®ONE solution to be installed at the Tri-Service General Hospital in Taiwan
02/04/2025
Louvain-La-Neuve, Belgium, April 2 nd , 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the [...]
IBA signe un contrat pour installer une solution Proteus®ONE au Tri-Service General Hospital à Taïwan
02/04/2025
Louvain-la-Neuve, Belgique, le 2 avril 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le [...]
Curium Announces Approval of Generic DTPA - Kit for the Preparation of Technetium Tc 99m Pentetate Injection in the U.S.
02/04/2025
ST. LOUIS, April 02, 2025 (GLOBE NEWSWIRE) -- Curium announced today that the U.S. Food and Drug Administration approved its generic version of the Kit for the Preparation of Technetium Tc 99m Pentetate Injection, often [...]
Respilean Drops Exposed (MUST-READ): The Truth About Lung Support Big Pharma Doesn’t Want You to Know
02/04/2025
Thousands Are Ditching Inhalers and Breathing Easier with This Surprising Lung Supplement Backed by Nature and Science JUPITER, FLORIDA, April 02, 2025 (GLOBE NEWSWIRE) -- RESPILEAN In a world where we measure [...]
Global Healing’s Oxy-Powder® Demonstrates Powerful Gut Health Benefits in Citruslabs Study
02/04/2025
Global Healing's Oxy-Powder® demonstrated significant digestive health benefits in a recent Citruslabs study, with 95% of participants reporting constipation relief. The ozonated magnesium formula addresses root causes [...]
Portsmouth Square Completes Strategic Refinancing of Hilton San Francisco Financial District Hotel
02/04/2025
SAN FRANCISCO, CA, April 01, 2025 (GLOBE NEWSWIRE) -- Portsmouth Square, Inc. (OTC: PRSI) ("Portsmouth Square" or "the Company") today announced the successful refinancing of its flagship asset, the Hilton San Francisco [...]
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order
02/04/2025
TORONTO, ONTARIO, April 01, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“ COSCIENS ” or the “ Company ”), a life science company which develops and commercializes a diversified portfolio [...]
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/04/2025
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for [...]
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
01/04/2025
Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort Topline results from NATiV3 projected in the second half of 2026 and, if positive, expected to be [...]
Inventiva annonce la fin du recrutement de l’étude clinique de Phase 3 NATiV3 évaluant lanifibranor chez les patients atteints de MASH et de fibrose avancée
01/04/2025
Objectifs de recrutement dépassés avec 1.009 patients randomisés dans la cohorte principale et 411 dans la cohorte exploratoire Principaux résultats de NATiV3 attendus au deuxième semestre 2026 et, si positifs, ils [...]
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
01/04/2025
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ®  platform to develop drug-Fc conjugate (DFC) immunotherapies, today [...]

Pages